Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P04637 (
p53
)
77,613
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
SIRT1 is a protein deacetylase that regulates cellular responses to a variety of stresses. In a recent issue of Molecular Cell, Kim et al. (2007) report the identification of a cellular protein,
AROS
, that activates the SIRT1-mediated deacetylation of
p53
.
...
PMID:AROuSing SIRT1: identification of a novel endogenous SIRT1 activator. 1796 66
The NAD(+)-dependent deacetylase SIRT1 is involved in diverse cellular processes, and has also been linked with multiple disease states. Among these, SIRT1 expression negatively correlates with cancer survival in both laboratory and clinical studies.
Active regulator of SIRT1
(
AROS
) was the first reported post-transcriptional regulator of SIRT1 activity, enhancing SIRT1-mediated deacetylation and downregulation of the SIRT1 target
p53
. However, little is known regarding the role of
AROS
in regulation of SIRT1 during disease. Here, we report the cellular and molecular effects of RNAi-mediated
AROS
suppression, comparing this with the role of SIRT1 in a panel of human cell lines of both cancerous and non-cancerous origins. Unexpectedly,
AROS
is found to vary in its modulation of
p53
acetylation according to cell context.
AROS
suppresses
p53
acetylation only following the application of cell damaging stress, whereas SIRT1 suppresses
p53
under all conditions analysed. This supplements the original characterization of
AROS
but indicates that SIRT1 activity can persist following suppression of
AROS
. We also demonstrate that knockdown of
AROS
induces apoptosis in three cancer cell lines, independent of
p53
activation. Importantly,
AROS
is not required for the viability of three non-cancer cell lines indicating a putative role for
AROS
in specifically promoting cancer cell survival.
...
PMID:Active regulator of SIRT1 is required for cancer cell survival but not for SIRT1 activity. 2425 75
Upon severe DNA damage a cellular signalling network initiates a cell death response through activating tumour suppressor
p53
in association with promyelocytic leukaemia (PML) nuclear bodies. The deacetylase Sirtuin 1 (SIRT1) suppresses cell death after DNA damage by antagonizing
p53
acetylation. To facilitate efficient
p53
acetylation, SIRT1 function needs to be restricted. How SIRT1 activity is regulated under these conditions remains largely unclear. Here we provide evidence that SIRT1 activity is limited upon severe DNA damage through phosphorylation by the DNA damage-responsive kinase HIPK2. We found that DNA damage provokes interaction of SIRT1 and HIPK2, which phosphorylates SIRT1 at Serine 682 upon lethal damage. Furthermore, upon DNA damage SIRT1 and HIPK2 colocalize at PML nuclear bodies, and PML depletion abrogates DNA damage-induced SIRT1 Ser682 phosphorylation. We show that Ser682 phosphorylation inhibits SIRT1 activity and impacts on
p53
acetylation, apoptotic p53 target gene expression and cell death. Mechanistically, we found that DNA damage-induced SIRT1 Ser682 phosphorylation provokes disruption of the complex between SIRT1 and its activator
AROS
. Our findings indicate that phosphorylation-dependent restriction of SIRT1 activity by HIPK2 shapes the
p53
response.
...
PMID:HIPK2 restricts SIRT1 activity upon severe DNA damage by a phosphorylation-controlled mechanism. 2611 41